Amit Sachdev Sells 4,520 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Amit Sachdev sold 4,520 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $163.01, for a total transaction of $736,805.20. Following the transaction, the executive vice president now directly owns 46,202 shares of the company’s stock, valued at $7,531,388.02. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Amit Sachdev also recently made the following trade(s):

  • On Monday, January 29th, Amit Sachdev sold 15,085 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $170.00, for a total transaction of $2,564,450.00.
  • On Friday, January 19th, Amit Sachdev sold 32,422 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $158.08, for a total transaction of $5,125,269.76.
  • On Monday, January 22nd, Amit Sachdev sold 46,172 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $158.65, for a total transaction of $7,325,187.80.

Vertex Pharmaceuticals Incorporated (VRTX) traded up $3.12 during trading hours on Wednesday, reaching $157.26. 1,901,860 shares of the company’s stock traded hands, compared to its average volume of 2,090,000. The stock has a market cap of $39,770.00, a P/E ratio of 80.65, a PEG ratio of 2.21 and a beta of 1.61. Vertex Pharmaceuticals Incorporated has a 12 month low of $84.39 and a 12 month high of $174.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.58 and a current ratio of 4.79.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.08. The company had revenue of $651.63 million for the quarter, compared to the consensus estimate of $592.49 million. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. Vertex Pharmaceuticals’s revenue was up 42.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.35 EPS. research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 1.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals announced that its board has authorized a stock repurchase program on Wednesday, January 31st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the pharmaceutical company to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

A number of equities research analysts recently weighed in on VRTX shares. HC Wainwright reiterated a “hold” rating and set a $103.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday. Maxim Group restated a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Deutsche Bank assumed coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, December 12th. They issued a “buy” rating and a $175.00 price target for the company. Royal Bank of Canada restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Finally, Oppenheimer boosted their price target on shares of Vertex Pharmaceuticals from $175.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-five have issued a buy rating to the stock. Vertex Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $183.11.

Several hedge funds have recently added to or reduced their stakes in VRTX. Dimensional Fund Advisors LP boosted its holdings in shares of Vertex Pharmaceuticals by 3.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 282,815 shares of the pharmaceutical company’s stock valued at $36,445,000 after acquiring an additional 9,882 shares during the last quarter. AHL Partners LLP purchased a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $916,000. Royal Bank of Canada boosted its holdings in shares of Vertex Pharmaceuticals by 67.4% in the 2nd quarter. Royal Bank of Canada now owns 141,971 shares of the pharmaceutical company’s stock valued at $18,295,000 after acquiring an additional 57,178 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Vertex Pharmaceuticals by 1,191.3% in the 2nd quarter. Janus Henderson Group PLC now owns 448,975 shares of the pharmaceutical company’s stock valued at $57,860,000 after acquiring an additional 414,206 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Vertex Pharmaceuticals by 1.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 274,237 shares of the pharmaceutical company’s stock valued at $35,341,000 after acquiring an additional 3,271 shares during the last quarter. 92.84% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/15/amit-sachdev-sells-4520-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply